• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-L1 表达水平与胰腺癌中的免疫应答呈正相关。

PD-L1 Expression Level Displays a Positive Correlation with Immune Response in Pancreatic Cancer.

机构信息

Department of Hepatobiliary and Pancreatic Surgery, First Hospital of China Medical University, Shenyang, Liaoning 110001, China.

Department of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning 110122, China.

出版信息

Dis Markers. 2020 Sep 25;2020:8843146. doi: 10.1155/2020/8843146. eCollection 2020.

DOI:10.1155/2020/8843146
PMID:33062072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7532998/
Abstract

The expression of PD-L1 could be a novel biomarker which predicts that patients are more likely to respond to immunotherapy. Our study investigated the relationship among clinicopathological characteristics, prognosis, PD-L1 expression levels, and FOXP3 Treg infiltration. In addition, the relationship among clinicopathological characteristics, prognosis, PD-L1 expression levels, and FOXP3 Treg infiltration was explored. Furthermore, the relationship between PD-L1 expression and FOXP3 Treg infiltration was examined. We found that 41.3% of pancreatic cancer patients had PD-L1-positive staining; both PD-L1 expression levels and FOXP3 Treg infiltration were significantly associated with depth of invasion, lymph node metastasis, distant metastasis, and pTNM. In addition, PD-L1 expression and FOXP3 Treg infiltration also could be prognostic biomarkers for pancreatic cancer.

摘要

PD-L1 的表达可能是一种新的生物标志物,可预测患者更有可能对免疫治疗产生反应。我们的研究调查了临床病理特征、预后、PD-L1 表达水平和 FOXP3+Treg 浸润之间的关系。此外,还探讨了临床病理特征、预后、PD-L1 表达水平和 FOXP3+Treg 浸润之间的关系。此外,还研究了 PD-L1 表达与 FOXP3+Treg 浸润之间的关系。结果发现,41.3%的胰腺癌患者存在 PD-L1 阳性染色;PD-L1 表达水平和 FOXP3+Treg 浸润均与浸润深度、淋巴结转移、远处转移和 pTNM 显著相关。此外,PD-L1 表达和 FOXP3+Treg 浸润也可能是胰腺癌的预后生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b047/7532998/f3e923cf7f93/DM2020-8843146.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b047/7532998/aca564931850/DM2020-8843146.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b047/7532998/f3e923cf7f93/DM2020-8843146.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b047/7532998/aca564931850/DM2020-8843146.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b047/7532998/f3e923cf7f93/DM2020-8843146.002.jpg

相似文献

1
PD-L1 Expression Level Displays a Positive Correlation with Immune Response in Pancreatic Cancer.PD-L1 表达水平与胰腺癌中的免疫应答呈正相关。
Dis Markers. 2020 Sep 25;2020:8843146. doi: 10.1155/2020/8843146. eCollection 2020.
2
PD-L1NEUT, Foxp3Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma.PD-L1NEUT、Foxp3Treg 和 NLR 作为新的预后标志物,对肝癌的生存获益价值较低。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211045820. doi: 10.1177/15330338211045820.
3
The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.程序性细胞死亡配体1和人类白细胞抗原I类在胰腺癌中的预后影响。
Cancer Med. 2017 Jul;6(7):1614-1626. doi: 10.1002/cam4.1087. Epub 2017 Jun 10.
4
Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.PD-1/PD-L1、CD8和FOXP3在胰腺导管腺癌中与促纤维增生性间质的预后价值、定位及相关性
Oncotarget. 2016 Jul 5;7(27):40992-41004. doi: 10.18632/oncotarget.10038.
5
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.肿瘤浸润淋巴细胞、程序性细胞死亡配体-1、CD8 和 FOXP3 在三阴性乳腺癌预后模型中的整合:对 244 例接受标准治疗的 I-III 期患者的分析。
Eur J Cancer. 2020 Sep;136:7-15. doi: 10.1016/j.ejca.2020.05.014. Epub 2020 Jul 1.
6
PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.PD-L1 是胰腺导管腺癌(PDAC)中癌症 FOXP3 的直接靶点,联合使用抗 PD-L1 和 CCL5 抗体的免疫疗法对 PDAC 的治疗有效。
Signal Transduct Target Ther. 2020 Apr 17;5(1):38. doi: 10.1038/s41392-020-0144-8.
7
CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.基于预测性综合免疫比值的 CD25 和 TGF-β 阻断抑制胰腺癌肿瘤生长。
J Transl Med. 2018 Oct 25;16(1):294. doi: 10.1186/s12967-018-1673-6.
8
Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.PD-L1 和肿瘤浸润淋巴细胞在下咽鳞状细胞癌中的预后及临床病理意义。
Oral Oncol. 2020 Mar;102:104560. doi: 10.1016/j.oraloncology.2019.104560. Epub 2020 Jan 7.
9
The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.Foxp3+/CD25+ 调节性 T 细胞和 PD-L1 表达在三阴性乳腺癌中的预测和预后价值。
Ann Diagn Pathol. 2019 Jun;40:143-151. doi: 10.1016/j.anndiagpath.2019.04.004. Epub 2019 Apr 10.
10
Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.阴茎鳞状细胞癌中的免疫检查点状态:一个北美队列研究。
Hum Pathol. 2017 Jan;59:55-61. doi: 10.1016/j.humpath.2016.09.003. Epub 2016 Sep 20.

引用本文的文献

1
Beta-glucans in oncology: revolutionizing treatment with immune power & tumor targeting.肿瘤学中的β-葡聚糖:凭借免疫能力和肿瘤靶向作用革新治疗方法。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug 27. doi: 10.1007/s00210-025-04519-8.
2
Research Progress on Th17/Treg Cell Imbalance in Epileptic Seizures.癫痫发作中Th17/Treg细胞失衡的研究进展
J Inflamm Res. 2025 Jun 13;18:7769-7779. doi: 10.2147/JIR.S524814. eCollection 2025.
3
The Mutation Portraits of Oncogenes and Tumor Supressor Genes in Predicting the Overall Survival in Pancreatic Cancer: A Bayesian Network Meta-Analysis.

本文引用的文献

1
The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors.实体瘤中检查点抑制剂的耐药机制。
Biomolecules. 2020 Apr 25;10(5):666. doi: 10.3390/biom10050666.
2
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy.胰腺导管腺癌:治疗障碍、肿瘤微环境与免疫疗法
World J Gastrointest Oncol. 2020 Feb 15;12(2):173-181. doi: 10.4251/wjgo.v12.i2.173.
3
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.胰腺癌:临床诊断、流行病学、治疗和结局的综述。
在胰腺癌中,通过预测总生存期的致癌基因和肿瘤抑制基因的突变特征:贝叶斯网络荟萃分析。
Asian Pac J Cancer Prev. 2023 Aug 1;24(8):2895-2902. doi: 10.31557/APJCP.2023.24.8.2895.
4
Characterization of neuroendocrine regulation- and metabolism-associated molecular features and prognostic indicators with aid to clinical chemotherapy and immunotherapy of patients with pancreatic cancer.利用临床化疗和免疫治疗帮助胰腺癌患者,对神经内分泌调节和代谢相关分子特征和预后指标进行分析。
Front Endocrinol (Lausanne). 2023 Jan 20;13:1078424. doi: 10.3389/fendo.2022.1078424. eCollection 2022.
5
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.血清生物标志物panel 诊断在胰腺导管腺癌中的应用:可溶性白细胞介素、IFN-γ、TNF-α 和 PD-1/PD-L1 与已建立的血清肿瘤标志物的临床效用比较。
J Cancer Res Clin Oncol. 2023 Jun;149(6):2463-2474. doi: 10.1007/s00432-022-04112-z. Epub 2022 Jun 23.
6
Exploration of the System-Level Mechanisms of the Herbal Drug FDY003 for Pancreatic Cancer Treatment: A Network Pharmacological Investigation.中药FDY003治疗胰腺癌的系统水平机制探索:一项网络药理学研究
Evid Based Complement Alternat Med. 2022 May 10;2022:7160209. doi: 10.1155/2022/7160209. eCollection 2022.
7
Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected Pancreatic Adenocarcinoma.切除胰腺腺癌中组织驻留记忆 T 细胞和肿瘤微环境特征的预后价值。
Balkan Med J. 2022 Jan 25;39(1):12-20. doi: 10.5152/balkanmedj.2021.21122. Epub 2021 Dec 20.
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861. doi: 10.3748/wjg.v24.i43.4846.
4
A novel MDSC-induced PD-1PD-L1 B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties.乳腺肿瘤微环境中一种由髓源性抑制细胞诱导产生的新型PD-1/PD-L1 B细胞亚群具有免疫抑制特性。
Oncoimmunology. 2018 Feb 20;7(4):e1413520. doi: 10.1080/2162402X.2017.1413520. eCollection 2018.
5
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.基质 PD-L1 阳性调节性 T 细胞和 PD-1 阳性 CD8 阳性 T 细胞定义了不同亚组非小细胞肺癌对 PD-1/PD-L1 阻断免疫治疗的反应。
J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.
6
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.用于癌症免疫治疗的PD-1和PD-L1检查点信号抑制:机制、联合应用及临床结果
Front Pharmacol. 2017 Aug 23;8:561. doi: 10.3389/fphar.2017.00561. eCollection 2017.
7
New strategies for cancer immunotherapy: targeting regulatory T cells.癌症免疫疗法的新策略:靶向调节性T细胞。
Genome Med. 2017 Jan 27;9(1):10. doi: 10.1186/s13073-017-0402-8.
8
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.膀胱癌中PD-1/PD-L1免疫检查点综述:从免疫逃逸介质到治疗靶点
Urol Oncol. 2017 Jan;35(1):14-20. doi: 10.1016/j.urolonc.2016.10.004. Epub 2016 Nov 3.
9
FoxP3 Expression in Macrophages, Cancer, and B Cells-Is It Real?巨噬细胞、癌症和B细胞中的FoxP3表达——这是真的吗?
Clin Rev Allergy Immunol. 2017 Jun;52(3):364-372. doi: 10.1007/s12016-016-8572-5.
10
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).免疫逃避 PD-L1/PD-1 阻断:成功(或失败)的七个步骤。
Ann Oncol. 2016 Aug;27(8):1492-504. doi: 10.1093/annonc/mdw217. Epub 2016 May 20.